Public Health Ontariogrid.415400.4, Toronto, Ontario, Canada.
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Microbiol Spectr. 2021 Oct 31;9(2):e0080321. doi: 10.1128/Spectrum.00803-21. Epub 2021 Oct 6.
Haemophilus influenzae can cause serious invasive disease. We report the epidemiology and antimicrobial susceptibility of invasive H. influenzae in Ontario, Canada, from 2014 to 2018 from laboratory-based data. Blood was the most common specimen source (89.5%). Consistent with widespread vaccination against serotype b (Hib), the incidence of Hib in Ontario remained low (0.04 cases per 100,000 population). H. influenzae disease primarily afflicted those <1 and ≥65 years of age. From 2014 to 2018, cases of invasive H. influenzae increased 5.6%, from 1.67 to 2.06 cases per 100,000 population, the majority of which were attributed to a 7.6% increase in the incidence of H. influenzae in those ≥65 years old. H. influenzae disease was primarily caused by nontypeable H. influenzae (NTHi) (74.2%) and, to a much lesser extent, serotype a (Hia) (8.9%) and serotype f (Hif) (10.2%). Serotype-dependent trends in antimicrobial susceptibility were observed. Hia and Hif isolates were predominantly susceptible to all antibiotics tested, while 27.2% of NTHi isolates were nonsusceptible to ampicillin. Resistance to ceftriaxone and meropenem, first-line antibiotics for invasive disease treatment, was nonexistent. The incidence of invasive H. influenzae in Ontario is increasing. The incidence and antimicrobial susceptibility of all serotypes and nontypeable H. influenzae should be monitored. H. influenzae can cause serious invasive, life-threatening disease and is considered 1 of 12 priority pathogens by the World Health Organization. Widespread vaccination against H. influenzae serotype b (Hib) has resulted in very low incidence of Hib in Ontario and other regions that have vaccination programs. However, the epidemiology of non-Hib serotypes and nontypeable H. influenzae (NTHi) remains poorly understood. Here, we describe the epidemiology of all invasive H. influenzae isolates (N = 1,338) received by our laboratory over the 5-year period and report on the antimicrobial susceptibility patterns by serotype. Overall, we observed an increase in the incidence of invasive disease over the study period, primarily driven by NTHi. Serotype-dependent trends in antimicrobial susceptibility were also observed. This work contributes to the global understanding of H. influenzae epidemiology and antimicrobial resistance and is additionally important for further vaccine planning initiatives.
流感嗜血杆菌可导致严重的侵袭性疾病。我们报告了 2014 年至 2018 年期间,加拿大安大略省基于实验室数据的侵袭性流感嗜血杆菌的流行病学和抗菌药物敏感性。血液是最常见的标本来源(89.5%)。由于广泛接种针对 b 型(Hib)的疫苗,安大略省 Hib 的发病率仍然很低(每 10 万人中 0.04 例)。流感嗜血杆菌病主要影响 1 岁以下和≥65 岁的人群。2014 年至 2018 年,侵袭性流感嗜血杆菌病例增加了 5.6%,从每 10 万人中 1.67 例增加到 2.06 例,其中大部分归因于≥65 岁人群中 Hib 发病率增加了 7.6%。流感嗜血杆菌病主要由非定型流感嗜血杆菌(NTHi)(74.2%)引起,其次是 a 型(Hia)(8.9%)和 f 型(Hif)(10.2%)。观察到血清型依赖性的抗菌药物敏感性趋势。Hia 和 Hif 分离株对所有测试的抗生素均高度敏感,而 27.2%的 NTHi 分离株对氨苄西林耐药。对治疗侵袭性疾病的一线抗生素头孢曲松和美罗培南无耐药性。安大略省侵袭性流感嗜血杆菌的发病率正在增加。应监测所有血清型和非定型流感嗜血杆菌的发病率和抗菌药物敏感性。流感嗜血杆菌可引起严重的侵袭性、危及生命的疾病,被世界卫生组织列为 12 种优先病原体之一。广泛接种 Hib 疫苗已使安大略省和其他有疫苗接种计划的地区 Hib 的发病率非常低。然而,非 Hib 血清型和非定型流感嗜血杆菌(NTHi)的流行病学仍知之甚少。在这里,我们描述了 5 年来我们实验室收到的所有侵袭性流感嗜血杆菌分离株(N=1338)的流行病学,并报告了血清型的抗菌药物敏感性模式。总的来说,我们观察到研究期间侵袭性疾病的发病率有所增加,主要是由 NTHi 引起的。还观察到血清型依赖性的抗菌药物敏感性趋势。这项工作有助于全球了解流感嗜血杆菌的流行病学和抗药性,对于进一步的疫苗规划倡议也很重要。